Sonnet BioTherapeutics, Inc.

  • Home
  • About
    • Overview
    • Management Team
    • Board of Directors
    • CEO Corner
  • Technology
    • Overview
    • Platform
    • Publications
  • Pipeline
    • Overview
    • SON-1010
    • SON-1210
    • SON-080
    • Clinical Trials
  • Partnering
  • News & Media
    • Press Releases
    • Presentations
    • Events
  • Investors
    • Overview
    • News & Events
    • Company Info
    • Stock Data
    • SEC Filings
    • Governance
  • Contact

Press Releases

News & Media

News & Media

  • Press Releases
  • Presentations
  • Events
Aug 16, 2021 6:30am EDT

Sonnet BioTherapeutics Provides Fiscal Year 2021 Third Quarter Business and Earnings Update

Jun 14, 2021 7:45am EDT

Sonnet BioTherapeutics Announces Change in Date of Annual Meeting

Jun 08, 2021 4:30pm EDT

Sonnet BioTherapeutics Announces Issuance of U.S. Patent for Platform Technology

May 17, 2021 7:00am EDT

Sonnet BioTherapeutics Provides Fiscal Year 2021 Second Quarter Business and Earnings Update

May 10, 2021 6:30am EDT

Sonnet BioTherapeutics Completes Successful GLP Repeat Dose Toxicology Study of IL12-FHAB (SON-1010) in Non-Human Primates (NHP)

May 03, 2021 6:00am EDT

Sonnet BioTherapeutics Completes Licensing Agreement with New Life Therapeutics

Mar 29, 2021 4:30pm EDT

Sonnet BioTherapeutics Provides 2021 Business Update

Mar 22, 2021 7:00am EDT

Sonnet BioTherapeutics Appoints Richard Kenney as Chief Medical Officer and Manuel Dafonseca as Head of Clinical Operations

Feb 16, 2021 8:10am EST

Sonnet BioTherapeutics Provides Fiscal Year 2021 First Quarter Business and Earnings Update

Feb 03, 2021 6:30am EST

Sonnet BioTherapeutics Announces Abstract Accepted for Presentation at AACR 2021 Annual Meeting

RSS
  • Prev
    • 1...
    • 3
    • 4
    • 5
    • 6
    • 7
    • 8
    • 9
    • 10
    • 11
    • 12
    Next
    © 2025 Sonnet BioTherapeutics, Inc. All Rights Reserved.
    Privacy Policy Disclaimer Sitemap